Eslam B. Elkaeed - researchr alias

researchr

You are not signed in
Sign in
Sign up

Viewing Publication 1 - 3 from 3

2023

Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducersIbrahim H. Eissa, Reda G. Yousef, Hazem Elkady, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mostafa. A. Elhendawy, Murrell Godfrey, Ahmed M. Metwaly. CANDC, 107:107953, December 2023. [doi]

d]pyrimidines as anti-cancer agents and apoptosis inducers targeting VEGFR-2Souad A. El-Metwally, Abdelrahman A. Abuelkhir, Hazem Elkady, Mohammed S. Taghour, Ibrahim M. Ibrahim, Dalal Z. Husein, Aisha A. Alsfouk, Ahlam Sultan, Ahmed Ismail, Samy Y. Elkhawaga, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa. CANDC, 106:107928, October 2023. [doi]

New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studiesHazem Elkady, Abdelrahman A. Abuelkhir, Mahmoud Rashed, Mohammed S. Taghour, Mohammed A. Dahab, Hazem A. Mahdy, Alaa Elwan, Hanan A. Al-ghulikah, Eslam B. Elkaeed, Ibrahim M. Ibrahim, Dalal Z. Husein, Ahmed M. Metwaly, Ibrahim H. Eissa. CANDC, 107:107958, December 2023. [doi]

Sign in or sign up to see more results.

runs on WebDSL